medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2005, Number 3

<< Back Next >>

Arch Neurocien 2005; 10 (3)

Oligodendrogliomas in the national institute of neurology and neurosurgery mvs: biologic behavior in a defined population

Moreno-Jiménez S, Alonso-Vanegas M, Bramasco AA, García-Pastor C, Terrazo-Lluch J, Tena M, Aguirre L

Language: Spanish
References: 32
Page: 140-145
PDF size: 182.31 Kb.


ABSTRACT

Oligodendrogliomas represent 2 to 5% of the intracraneal tumors. Usually these tumors are diagnosed between the 4th and the 5th decades of life. The most commonly site is the frontal lobe. Surgery is the milestone of the treatment approach. Material and methods: between January 1990 and January 2000, 28 patients had a diagnosis of oligodendroglioma. We looked for locali-zation, signs and symtoms of presentation, peroperative diagnosis, histopathology, type of treatment received and complications. Results: the most frecuent site was the frontal lobe (43%), while the main symptom of presentation were seizures (61%). The preoperative diagnosis with clinical data and imaging was low-grade glioma in 39% of the cases. Partial resection was performed in 36% of the cases being the most prevalent of all treatments. The surgery was performed by neurosurgeons in half the cases and by residents of the last year in the other half. Seventy one porcent of patients were treated with radiotherapy, and 21% with chemotherapy. The hystopathologic diagnosis was oligodendroglioma in 71% and anaplastic oligoden-droglioma in 29%. The operative mortality was 8%. Conclusion: our results are similar to the ones described in the literature.


REFERENCES

  1. Nijjar TS, Simpson WJ, Gadalla T, Math M, McCartney M. Oligodendroglioma The Princess Margaret Hospital experience (1958-1984). Cancer 1993;71:4002-6.

  2. Mork SJ, Lindegaard KF, Halvorsen TB. Oligodendroglioma: Incidence and biological behavior in a defined population. J Neurosurg 1985;63:881-9.

  3. Shaw EG, Scheithauer BW, O´Fallon JR. Oligodendrogliomas: The Mayo Clinic experience. J Neurosurg 1992;76:428-34.

  4. Lindegaard KF, Mork SJ, Eide GE. Statistical analysis of clinicopathological features, radiotherapy, and survival in 170 cases of oligodendroglioma. J Neurosurg 1987;67:224-30.

  5. Russell DS, Rubenstein LJ. Eds. Pathology of tumors of the central nervous system. Baltimore: Williams and Wilkins, 1989.

  6. Chin HW, Hazel JJ, Kim TH, Webster JH. Oligodendrogliomas. I. A clinical study of cerebral oligodendrogliomas. Cancer 190;45:1458-66.

  7. Earnest F III, Kernohan JW, Craig WM. Oligodendrogliomas. A review of two hundred cases. Arch Neurol Psychiatry 1950; 63:964-76.

  8. Horrax G, Wu WQ. Postoperative survival of patients with intracranial oligodendroglioma with special reference to radical tumor removal. J Neurosurg 1951;8:473-9.

  9. Dohrmann GJ, Farwell JR, Flannery JT. Oligodendrogliomas in Children. Surg Neurol 1978;10:21-5.

  10. Backus RE, Millichap JG. The seizure as a manifestation of intracranial tumor in childhood. Pediatrics 1962;29:978-84.

  11. Berkheiser SW. Oligodendrogliomas in the young-age group. J Neurosurg 1956;13:170-5.

  12. Farwell JR, Dormán GJ, Flannery JT. Central nervous system tumors in children. Cancer 1977;40:3123-32.

  13. Freeman L, Feigin I. Oligodendroglioma with 35-year survival. J Neurosurg 1963;20:363-5.

  14. Gass A, Van Wagenen WP. Oligodendroglioma in pre-adolescence. Report of a case. J Neurosurg 1950;7:374-6.

  15. Roberts M, German WJ. Oligodendroglioma: a 40-year survival. Case report. J Neurosurg 1969;31:355-7.

  16. Weir B, Elvidge AR. Oligodendrogliomas: an analysis of 63 cases. J Neurosurg 1968;29:500-5.

  17. Kalan C, Burrows EH. Calcification in intracranial gliomata. Br J Radiol 1962; 35:589-602.

  18. Vonofakos D, Marcu H, Hacker H. Oligodendrogliomas: CT patterns with emphasis on features indicating malignancy. J Comut Assist Tomogr 1979;3:783-8.

  19. Rees J, Lee SH, Smirniotopoulos. Primary brain tumors in adults. In: Lee SH, Rao KCVG, Zimmerman RA, eds. Cranial MRI and CT. McGraw-Hill International Edition 1999.

  20. Lee YY, Van Tassel PV. Intracranial oligodendrogliomas:Imaging findings in 35 untreated cases. AJNR 1989;10:119-27.

  21. Vigneron DB, Nelson SJ. Magnetic resonance spectroscopy. In: Bernstein M, Berger MS, eds. Neuro-oncology the essentials. Thieme New York; 2000;99-113.

  22. Plunkett SR. Conventional radiotherapy of specific central nervous system tumors. In: Wilkins RH, Rengachary SS, eds. Neurosurgery. McGraw-Hill 1996.

  23. Shimizu KT, Tran LM, Mark RJ, Selch MT. Management of oligodendrogliomas. Radiology 1993;186:569-72.

  24. Fortin D, Cairncross GJ, Hammond RR. Oligodendroglioma: An appraisal of recent data pertaining to diagnosis and treatment. Neurosurgery 1999;45:1279-91.

  25. Cairncross JG, McDonald D, Ludwin S. Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol 1994;12:2013-21.

  26. Cairncross JG, Ueki K, Zlatescu MC. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90:1473-9.

  27. Ino Y, Zlatescu MC, Sasaki H. Long Survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. J Neurosurg 2000;92:983-90.

  28. Streffer J, Schabert M, Bamberg M. A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors. J Neurol 2000;247:297-302.

  29. He J, Hoang-Xuan, Marie Y. P18 tumor suppressor gene and progression of oligodendrogliomas to anaplasia. Neurology 2000;55:867-9.

  30. Gonzales M, Sheline GE. Treatment of oligodendrogliomas with or without postoperative radiation. J Neurosurg 1998; 68:684-8.

  31. Sun Genka S, Shitara N. Factors Possibly Influencing the Prognosis of Oligodendroglioma. Neurosurgery 1988;22:886-91.

  32. Félix IA. Tumores de células neurogliales. En: Félix IA ed. Atlas de neuropatología. Auroch 2000;1-26.




2020     |     www.medigraphic.com